Company: LIMN
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001104659-25-055078
Chunk: 6

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 6
---
 by reference to pages 52-75 in the Annual Report on Form 10-K for the year ended December 31, 2024 filed by Iris with the SEC on April 16, 2025 (the “Iris Form 10-K”).

The unaudited financial statements
of Iris for the three months ended March 31, 2025 and 2024 are filed herewith as Exhibit 99.7.

Properties

The business address of Liminatus’s
principal executive office is 6 Centerpointe Dr. #625, La Palma, California 90623.

The Company believes that
all of its properties have been adequately maintained, are generally in good condition, are suitable and adequate for its business.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion
and Analysis of Financial Condition and Results of Operations of Liminatus for the fiscal years ended December 31, 2024 and 2023
is set forth below.

Unless the context otherwise requires, for purposes of this section, the terms “we,” “us,” “our,” “the Company” or “Liminatus” refer to Liminatus Pharma, LLC prior to the consummation of the Business Combination. You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this report. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks, uncertainties, and assumptions. As a result of many factors, including those set forth in the “Risk Factors” section of this filing, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a pre-clinical
stage life sciences and pre-revenue company developing a next generation CD47 checkpoint inhibitor under a license agreement. In October 2022,
the Company was assigned a license and development agreement, as amended, with InnoBation Bio Co. Ltd (“InnoBation”) (the
“CD47 License”), whereby, effective March 31, 2023, the Company received an exclusive license to develop and commercialize
products for the CD47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD47
products (collectively, “CD47 Products”), from Cur